The “Shocking Truth” Behind Bill Adams’ Dangerous Public Advertising For Off-Label Use of GalaFLEX…For years, a surgeon-marketeer and paid industry consultant, named William P. Adams Jr. MD, has been advertising the off-label use of a…May 28A response icon1May 28A response icon1
Have You Experienced a Complication or Breast Cancer Recurrence After Breast Surgery Using GalaFLEX…If you are a patient who has undergone a cosmetic or breast reconstructive surgery following a cancer diagnosis, you may have been treated…May 27May 27
A Warning to U.S.Recently a major U.S. commercial insurance carrier, CIGNA, made the unilateral decision to proclaim that GalaFLEX mesh is “medically…May 27A response icon1May 27A response icon1
CIGNA CEO’s Dangerous Decision to Reimburse American Breast Surgeons For Use of GalaFLEX in…David Cordani is the CEO of one of America’s most powerful and largest health insurers.May 24A response icon1May 24A response icon1
A Response to Humacyte CEO’s Press Release of 4/18/2025Dear Dr. Niklason,Apr 19A response icon4Apr 19A response icon4
Rooting Out Healthcare “Fraud-on/at-FDA” Needs a Precision Scalpel, Not a Chainsaw: The False…The Trump administration is aiming to limit fraud, misuse and abuse of taxpayer dollars by the federal administrative state. It has…Feb 22Feb 22
The Coming Sea Change at Trump’s FDA: Towards an Era of Safety and Public Transparency for Medical…It has been over a decade since my late-wife, Dr. Amy Josephine Reed, was harmed and killed by a poorly regulated medical device, known as…Dec 8, 2024A response icon1Dec 8, 2024A response icon1
Medical Device Safety and The Promise of Robert F.President-elect Donald J. Trump’s embrace of Robert F. Kennedy Jr’s Make America Healthy Again (MAHA) directive is one of the most…Dec 2, 2024Dec 2, 2024
Princess of Wales, Catherine Middleton, Has A Potential Uterine Leiomyosarcoma (uLMS): A Delayed…The gynecological “Assumption of Benignity” about symptomatic uterine fibroids in one in 200–400 women causes a dangerous delay in…Mar 30, 2024A response icon3Mar 30, 2024A response icon3